Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148489 | 1.00 | KIF11 (0.60) | KIF11 | |
| SCHEMBL1268931 | 1.00 | KIF11 (0.60) | KIF11 | |
| SCHEMBL22361680 | 0.96 | KIF11 (0.61) | KIF11 | |
| SCHEMBL14935909 | 0.96 | KIF11 (0.61) | KIF11 | |
| SCHEMBL1905808 | 0.96 | KIF11 (0.61) | KIF11 | |
| SCHEMBL21690007 | 0.92 | KIF11 (0.54) | KIF11 | |
| SCHEMBL29634957 | 0.91 | KIF11 (0.49) | KIF11 | |
| SCHEMBL12475659 | 0.86 | KIF11 (0.62) | KIF11 | |
| SCHEMBL12475661 | 0.86 | KIF11 (0.62) | KIF11 | |
| SCHEMBL31562941 | 0.86 | KIF11 (0.47) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305994-A1 | Antagonistic DR3 Ligands | NOVO NORDISK AS (DK) | 2017-10-26 | — | — | US | disclosed |
| US-9737612-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-08-22 | — | — | US | disclosed |
| US-9713644-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2017-07-25 | — | — | US | disclosed |
| EP-2536434-B1 | PURIFICATION METHOD | NOVO NORDISK AS (DK) | 2016-04-20 | — | — | EP | disclosed |
| US-9234192-B2 | Conjugated proteins | NOVO NORDISK A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| EP-2536752-B1 | Modified recombinant Factor VIII | NOVO NORDISK AS (DK) | 2015-04-08 | — | — | EP | disclosed |
| US-20140294853-A1 | ANTAGONISTIC DR3 LIGANDS | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-8765130-B2 | Antagonistic DR3 ligands | NOVO NORDISK A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| EP-2681237-A1 | ANTAGONISTIC DR3 LIGANDS | Novo Nordisk A/S (DK) | 2014-01-08 | — | — | EP | disclosed |
| US-20130336984-A1 | ANTAGONISTIC DR3 LIGANDS | NOVO NORDISK A/S (DK) | 2013-12-19 | — | — | US | disclosed |
| US-20130330360-A1 | ANTAGONISTIC DR3 LIGANDS | NOVO NORDISK A/S (DK) | 2013-12-12 | — | — | US | disclosed |
| US-20130012684-A1 | Purification Method | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130004524-A1 | Conjugated Proteins | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| EP-2536752-A1 | CONJUGATED PROTEINS | Novo Nordisk A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536434-A2 | PURIFICATION METHOD | Novo Nordisk A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012117067-A1 | ANTAGONISTIC DR3 LIGANDS | NOVO NORDISK A/S (DK) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011101261-A2 | PURIFICATION METHOD | NOVO NORDISK A/S (DK) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101277-A1 | CONJUGATED PROTEINS | NOVO NORDISK A/S (DK) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130330360-A1 | ANTAGONISTIC DR3 LIGANDS | HAVCR2, CD58, FCGR3B | KIF11 4488/4885 |
| US-20170305994-A1 | Antagonistic DR3 Ligands | ACKR3, FPR3, FCGR3B | KIF11 4159/4885 |
| US-20130336984-A1 | ANTAGONISTIC DR3 LIGANDS | ACKR3, FPR3, FCGR3B | KIF11 4159/4885 |
| US-20130004524-A1 | Conjugated Proteins | F13B, F5, F13A1 | KIF11 1990/4885 |
| US-20130012684-A1 | Purification Method | ALB, CD2BP2, S100P | KIF11 3289/4885 |
| US-20140294853-A1 | ANTAGONISTIC DR3 LIGANDS | ACKR3, FPR3, FCGR3B | KIF11 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.